Open AccessINVEST: Results of combined strategies to control blood pressure
Author(s) -
Kolloch Rainer E.
Publication year - 2001
Publication title -
clinical cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.263
H-Index - 72
eISSN - 1932-8737
pISSN - 0160-9289
DOI - 10.1002/clc.4960241705
Subject(s) - medicine , trandolapril , blood pressure , cardiology , coronary artery disease , verapamil , diabetes mellitus , aortic pressure , pulse pressure , intensive care medicine , ace inhibitor , endocrinology , calcium , angiotensin converting enzyme
The treatment of hypertension continues to be challenging due to the lack of understanding regarding underlying modulators of blood pressure as well as co‐existing conditions such as atherosclerosis and diabetes. This has led to uncertainty regarding treatment strategy and intensity. The INternational VErapamil SR/trandolapril STudy (INVEST) is designed to evaluate the relationship between cardiovascular risk and blood pressure modulators. Based on a review of preliminary data, it appears that the treatment regimen used in the INVEST trial has been more successful than other studies at controlling systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse pressure. These preliminary data from INVEST suggest that a high proportion of coronary artery disease (CAD) patients with hypertension should receive combination therapy to achieve contemporary blood pressure targets.